Detalhe da pesquisa
1.
Evolution and impact of subclonal mutations in chronic lymphocytic leukemia.
Cell
; 152(4): 714-26, 2013 Feb 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-23415222
2.
Mechanism of EBV inducing anti-tumour immunity and its therapeutic use.
Nature
; 590(7844): 157-162, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33361812
3.
Genetic events associated with venetoclax resistance in CLL identified by whole-exome sequencing of patient samples.
Blood
; 142(5): 421-433, 2023 08 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-37146250
4.
Growth dynamics in naturally progressing chronic lymphocytic leukaemia.
Nature
; 570(7762): 474-479, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31142838
5.
Activation of the MAPK pathway mediates resistance to PI3K inhibitors in chronic lymphocytic leukemia.
Blood
; 138(1): 44-56, 2021 07 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33684943
6.
miR-29 modulates CD40 signaling in chronic lymphocytic leukemia by targeting TRAF4: an axis affected by BCR inhibitors.
Blood
; 137(18): 2481-2494, 2021 05 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33171493
7.
Idelalisib reduces regulatory T cells and activates T helper 17 cell differentiation in relapsed refractory patients with chronic lymphocytic leukaemia.
Br J Haematol
; 197(2): 207-211, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35170759
8.
Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL.
Blood
; 136(25): 2918-2926, 2020 12 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-32603412
9.
MYD88 L265P mutations identify a prognostic gene expression signature and a pathway for targeted inhibition in CLL.
Br J Haematol
; 184(6): 925-936, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30537114
10.
Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia.
Blood
; 128(4): 574-83, 2016 07 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-27235137
11.
Human C1-Inhibitor Suppresses Malaria Parasite Invasion and Cytoadhesion via Binding to Parasite Glycosylphosphatidylinositol and Host Cell Receptors.
J Infect Dis
; 213(1): 80-9, 2016 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26347576
12.
IL4-STAT6 signaling induces CD20 in chronic lymphocytic leukemia and this axis is repressed by PI3Kδ inhibitor idelalisib.
Haematologica
; 106(11): 2995-2999, 2021 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34196167
13.
Targeting constitutively active STAT3 in chronic lymphocytic leukemia: A clinical trial of the STAT3 inhibitor pyrimethamine with pharmacodynamic analyses.
Am J Hematol
; 96(4): E95-E98, 2021 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33373063
14.
SF3B1 and other novel cancer genes in chronic lymphocytic leukemia.
N Engl J Med
; 365(26): 2497-506, 2011 Dec 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-22150006
15.
Analysis of ITGB2 rare germ line variants in chronic lymphocytic leukemia.
Blood
; 130(22): 2443-2444, 2017 11 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-29051179
16.
LNA-mediated anti-miR-155 silencing in low-grade B-cell lymphomas.
Blood
; 120(8): 1678-86, 2012 Aug 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-22797699
17.
A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.
Haematologica
; 98(6): 964-70, 2013 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-23645694
18.
Rare Germline ATM Variants Influence the Development of Chronic Lymphocytic Leukemia.
J Clin Oncol
; 41(5): 1116-1128, 2023 02 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36315919
19.
Circulating Th17 T cells at treatment onset predict autoimmune toxicity of PI3Kδ inhibitors.
Blood Cancer J
; 13(1): 22, 2023 02 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36732326
20.
Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance.
Blood Adv
; 7(9): 1929-1943, 2023 05 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36287227